Bibliografia
1. Kälble T, Lucan M., Nicita G., Sells S., Burgos Revilla FJ, Wiesel M: EAU Guidelines on renal transplantation, updated March 2004
2. Nord Italia Transplant. Centro Immunotrasfusionale e di Immunologia dei Trapianti. Ospedale Maggiore
3. Penn I. Transplantation of kidneys containing primary malignant tumors. Transplantation 1973; 16: 674-5.
4. . European best practice guidelines for renal transplantation. Nephrol Dial Transplant (2000) 15 (suppl 7) 1-85 e 6-7; (2002) 17 (suppl 4) 1-5. Adams J, Gudemann C, Mohring K, Mehls O, Wiesel M. Renal transplantation in children with malformations of the urinary tract. Transplant Proc 2002;34:726-727.
Abstract&itool=iconnoabstr
6. Crowe A, Cairns HS, Wood S, Rudge CJ, Woodhouse CR, Neild GH. Renal transplantation following renal failure due to urological disorders. Nephrol Dial Transplant 1998;13:2065-2069. Abstract&itool=iconfft
7. Dipartimento di Nefro-urologia e Trapianto Renale Centro di Tipizzazione e Immunologia dei Trapianti Laboratorio epidemiologico IRCCS Ospedale Maggiore Policlinico, Milano
8. Registro Svizzero della Salute dei Donatori d’Organo
9. Dipartimento di clinica medica nefrologia e scienze della prevenzione 10. Dati report 2005-2006 del CNT e del SIT.
11. Giornale Italiano di Nefrologia / Vol. 16 n.1, 1999/pp. 59-66; Vol. 18 n. 4, 2001/pp. 444-450
12.Thistlethwaite JRJ, Woodle ES, Mayes JT, et al. Aggressive needle biopsy protocol prevents loss of renal allografts to undetected rejection during early posttransplant dysfunction. Transplant Proc 1989; 21: 1890-2.
13. Jain S, Curwood V, White SA, Williams ST, Doughman T, Nicholson ML.
Weekly protocol renal transplant biopsies allow detection of sub-clinical acute
rejection episodes in patients with delayed graft function.Transplant Proc 2000;
32:191.
14. Diem P, Redmon JB, Abid M, et al. Glucagon, cathecolamine and pancreatic polypeptide secretion in type 1 diabetic recipients of pancreas allografts. J Clin
Invest, 86: 2008–2013, 1990.
15. Pozza G, Traeger J, Dubernard JM, et al. Endocrine response of type 1 (insulin- independent) diabetic patients following successful pancreas transplantation.
Diabetologia, 24: 244–248, 1983.
16. Kendall, Rooney, Smets, et al. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long- standing type 1 diabetes and autonomic neuropathy.Diabetes, 46: 249–257, 1997.
17. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol, 42: 727–736, 1997.
18. Ramsay RC, Goetz FC, Sutherland DE, et al. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med,
318: 208–214, 1988.
19. Fioretto P, Steffes MW, Surtherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med, 339: 69–75, 1998.
20. Bilous RW, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin dependent diabetes. N Engl J Med, 321: 80–85, 1988.
21. Gaston RS, Alveranga DY, Becker BN, Distant DA, Held PJ, Bragg-Gresham JL, Humar A, Ting A, Wynn JJ, Leichtman AB: Kidney and pancreas transplantation.
Am J Transplant 3(Suppl 4):64–77, 2003
22. Istituto per lo studio e la cura del diabete - centro di diabetologia .
23. Robertson RP, Davis C, Larsen J, et al. Pancreas and islet transplantation for patients with diabetes mellitus ,Technical Review. Diabetes Care, 23: 112–116, 2000.
24. Cheung DH, Sutherland DE, Gillingham KJ, et al. Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients. Kidney Int, 41: 924–
929, 1992.
25. Sollinger HW, Odorico JS, Knechtle SJ, et al. Experience with 500 simultaneous pancreas-kidney transplants. Ann Surg, 228: 284–296, 1998.
26.Guessner RW, Dunn DL, Guessner AC, et al. Recipient risk factors have an impact on technical failure and patient and graft survival rates in bladder-drained pancreas transplant. Transplantation, 57: 1598–1606, 1994.
27. Venstrometal, JAMA 2003
28. Maryniak RK, Mendoza N, Clyne D, et al. Recurrence of diabetic nodular glomerulosclerosis in a renal transplant. Transplantation, 39: 35–38, 1985.
29. Starzl TE. History of clinical transplantation. World J Surgery 2000;24:759-82.
30. Steinmulle T, Neuhaus P, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2003;35(6):1529-35.
31. Ghobrial RM, Busuttil RW, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factor detrmining outcome in over 500 patients. Ann Surg 2001;234:384-93.
32. Humar A, Khwaja K, Sielaff TD, Lake J, Payne W. Technique of split-liver transplantation for two adult recipients. Liver transplantatio 2002;8(8):725-9.
33. Goldstein MJ, et al. Analysis of failure in living donor liver transplantation:
differential outcomes in children and adults. World J Surg 2003;27:356-34.
34. Broelsch CE, et al. Liver transplantation in children from living related donors.
Ann Surg 1991;214:428-39.
35. European liver transplant registry, 2006
36. Trapianto epatico nell’adulto, Italia, raccomandazioni della Società Italiana per lo studio del fegato (AISF)
37.Cecka JM. The UNOS Scientific Renal Transplant Registry: Ten Years of Kidney Transplants. In: Clinical Transplants 1997 Cecka JM, Terasaki PI, eds. Los Angeles, UCLA Tissue Typing Laboratory,1998; pp 1-14
38. Pescovitz MD, Barone G, Choc MGJ, et al. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: Twoyear
data in primary renal allograft recipients: A report of the Neoral Study Group.
Transplantation 1997; 63: 778 -80.
39. Rubin RH. Infectious diseases in transplantation/pre- and posttransplantation. In:
Norman DJ, Suki WN, Thorofare NJ, eds. Primer on Transplantation, edited by.
American Society of Transplant Physicians, 1998; pp 141-54.
40. Burke BA, Chavers BM, Gillingham KJ, et al. Chronic renal allograft rejection in the first 6 months post transplant . Transplantation 1995; 60: 1413-7.
41 . Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-9.
42. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 2129-34.
43. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, et al. (2003) Chronic renal failure after transplantation of a non renal organ. N Engl J Med 349: 931 940.
44.. Buell J, Trofe J, Hanaway MJ, Lo A, Rosengard B, Rilo H, Alloway R, Beebe T, First MR, Woodle ES: Transmission of donor cancer into cardiothoracic transplant recipients. Surgery 130 (4):660-66; discussion, 666-68, 2001
45. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JPA. Risk of neoplasia in renal transplant patients. Lancet 1995; 3 4 6 : 4 0 3 - 6 .
46. Penn I. Primary kidney tumours before and after renal transplantation.
Transplantation 59 (4):480-85, 1995
47. European best practice guidelines for renal transplantation (part 1). Nephrol Dial Transplant 15(Suppl 7):6-7, 2000
48. Sola R, Rodriguez S, Guirado L, Lopez-Navidad A, Caballero F, Diaz M, Baro E, Paredes D. Renal transplant for recipients over 60 years old. Transplantation 2000;69 (11):2460-2461.
49. Kauffman H, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumour Registry: donors with a history of cancer.
Transplantation 70 (12):1747-51, 2000
50. Kauffman H, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumour Registry: donors with a history of cancer.
Transplantation 2000;70 (12):1747-1751.
51. Penn I: Cancers complicating organ transplantation: (Editorial). New Engl J Med 323: 1767-1769, 1990.
52. Penn I: The changing patterns of post-transplant malignancies. Transplant Proc 23: 1101-1103, 1991.
53. Buzzeo B, Heisey DM, Messing EM. Bladder cancer in renal transplant recipients. Urology 1997;50 (4):525-528.
54 Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84: 985-92. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-65.
55. Aakhus S, Dahl K, Widerne TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 54: 648-54.
56. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease. Major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451-7.
57. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 4: S16-23.
58. Report from the National Kidney Foundation Task Force on Cardiovascular Disease. Controlling the epidemic of cardiovascular disease in chronic renal disease:
What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 5 (suppl. 3) S1-199.
59. Ojo AO, Port FK, Wolfe RA, et al. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994; 24: 59-64.
60. Cosio FG, Alamir A, Yim S, et al. Patient survival after renal transplantation: The impact of dialysis pre-transplant. Kidney Int 1998; 53: 767-72.
61. Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32: S120-41.
62. Frei U, Schindler R, Wieters D, et al. Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transplant 1995; 10: 1206.
63. Schnitzler MA, Woodward RS, Brennan DC, Spitznagel EL, Dunagan WC, Bailey TC. The effects of cytomegalovirus serology non graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation. Am J Kidney Dis 1 9 9 7 ; 29: 428-34.
64. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-70.
65. Aguado JM, Herrero JA, Gavalda, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain: Spanish Transplantation Infection Study Group, GESITRA.Transplantation 1997; 63: 1278-86 66. First MR: Living-related donor transplant should be performed with caution in patients with focal segmental glomerulosclerosis. Pediatr Nephrol 1995;9:S40-42.
67. Dantal J, Bigot E, Bogers W, et al.: Effect of plasma protein absorption on protein excretion in kidney transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994;330:7-14.
68. Manske CL. Pre-transplant cardiac evaluation. Graft. 2000;3:186-189.
69. Manske CL, Wilson RF, Wang Y, Thomas W. Atherosclerotic vascular complications in diabetic transplant candidates. Am J Kidney Dis. 1997;29:601-607.
70. Herrmann J, Lerman A. The endothelium: dysfunction and beyond. J Nucl Cardiol. 2001;8:197-206.
71. Auchincloss H, Shaffer D. Pancreas Transplantation. In: Ginns LC, Cosimi AB, Morris PJ, eds. Transplantation. Malden, Mass: Blackwell Science; 1999.
72.Drachenberg CB, Papadimitriou JC, Farney A, et al. Pancreas transplantation: the histologic morphology of graft loss and clinical correlations. Transplantation.
2001;71:1784-1791.
73. Sollinger HW, Odorico JS, Knechtle SJ, et al. Experience with 500 simultaneous pancreas-kidney transplants. Ann Surg, 228: 284–296, 1998.
74. Gruessner AC, Sutherland DE 2002 Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002. Clin Transpl 41–77
75. Stratta RJ, Taylor RJ, Sindhi R, Sudan D, Jerius JT, Gill IS 1996 Analysis of early readmissions after combined pancreas-kidney transplantation. Am J Kidney Dis 28:867–877
76. Hume DM, Magee JH, Kaufman MS, Rittenburg MS, Prout GR. Renal homotransplantation in man in modified recipients. Ann Surg 1963; 158: 608.
77. Robson AJ, Calne RY. Complication of urinary drainage following renal transplantation. Brit J Urol 1971; 43: 586.
78. Prieta M, Sutherland DER: Pancreas transplant results according to the technique of duct management: bladder versus enteric drainage. Surgery 84:633-639, 1987 79. Hickey DP, Bakthavatsalam R, Bannon CA, O’Malley K, Corr J, Little DM:
Urological complications of pancreatic transplantation. J Urol 157:2042-48, 1997 80. Boggi U, Mosca F:A technique for retroperitoneal pancreas transplantation with portalenteric drainage.Transplantation. 2005 May 15;79(9):1137-42.
81.Robertson RP (2004) Islet transplantation as a treatment for diabetes A work in progress. N Engl J Med 350: 694 705.
82. Busuttil R.W., Klintmalm G.B.: Transplantation of the Liver.W.B. Saunders Company, Philadelphia, 1996.
83. Roberts JP, Hulbert-Shearon TE, merion RM et al. Influence of graft type on outcomes after pediatric liver transplantation. Am J Transplant 2004;4:373-7.
84.Avolio AW, Agnes S, Nure E, Gasbarrini A, Siciliano M, Pompili M, Castagneto M. The non standard liver, a hidden resource that cannot be overlooked: implications for the identification of the best recipient. Transplant Proc. 2006 May, 38 (4):1055-8
85. Calne R, Moffatt SD, Friend PJ, et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68:
1613-6.
86. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2004; 361 (9368): 1502- 10.
87. Codreanu I, Cravedi P, Ruggenenti P, Remuzzi G. Antilymphocytem therapy in kidney transplantation: a prospective randomized trial of fulldose rabbit anti-human thymocyteglobulin (RATG) versus low-dose RATG and Basiliximab.
Transplantation 2004; 78: 276.
88. Pancreas after Kidney Transplants in Posturemic Patients with Type I Diabetes Mellitus, Angelika C. , Gruessner, David E. R., Sutherland, David L. Dunn, John S.
Najaran, Abhi Humar, Raja Kandaswamy and Rainer W. Department of Surgery, University of Minnesota, Minneapolis, Minnesota.
89. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation: a randomized multicentre study. Lancet 2002 90. Groth, Backman, Morales, et al. Sirolimus (rapamycin) based therapy in human renal transplantation:Similar efficacy and different toxicity compared with cyclosporine: Sirolimus European Renal Transpl ant Study Group.Transplantation 1999; 67: 1036-42.
91. The European Mycophenolate Mofetil Co-operative Study Group: Placebo controlled study of Mycophenolate Mofetil combined with cyclosporine and corticosteroids to the prevention of acute rejection. Lancet 1995; 345: 1321-5.
92. Hollander AA, Hene RJ, Hermans J, Van Es LA, van der Woude FJ. Late prednisone withdrawal in cyclosporine treated kidney transplant patients: A randomized study. J Am Soc Nephrol 1997; 8: 294-301.
93. Opelz G: Efficacy of rejection prophylaxis with OKT3 in renal transplantation.
Collaborative Transplant Study. Transplantation 1995
94.Patton PR, Brunson ME, Pfaff WW, Howard RJ, Peterson JC, Ramos EL, Karlix JL: A preliminary report of diltiazem and ketoconazole : Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 57: 889-92, 1994
95. Churchill BM, Jayanthi RV, McLorie GA, Khoury AE: Paediatric renal transplantation into the abnormal urinary tract. Pediatr Nephrol 10: 113-20, 1996 96. Calman KC, Bell PR, Briggs JD, Hamilton DN, MacPherson SG, Paton AM:
Bilateral nephrectomy prior to renal transplantation. Br J Surg 63: 512-16, 1976 97. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P: Cancer in paztients on dialysis for end-stage renal disease : an international collaborative study. Lancet 354: 93-99, 1999
98. Penn I: Occurrence of cancers in immunosuppressed organ transplant recipients.
Clin Transpl; s147-58, 1998
99. Kliem V, Kolditz M, Behrend M, et al. Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 1997; 11: 255-8.
100. Sheil AGR, Disney APS, Mathew TG, Amiss N. De novo m a l ignancy emerges as a major cause of morbidity and late failure
in renal transplantation. Transplant Proc 1993; 25: 1383-4.
101.Bokemeyer C, Thon WF, Brunkhorst T, Kuczyk MA, Pichlmayr R, Kliem V. High frequency of urothelial cancers in patients
with kidney transplantations for end-stage analgesic nephropathy.
J Cancer 1996; 32A: 175-6.
102. Siebels M, Theodorakis J, Liedl B, Schneede P, Hofstetter A: Large de novo renal cell carcinoma in a 10-year-old transplanted kidney. Transplantation 69:677–79, 2000
103. Roy C, El Ghali S, Buy X, Lindner V, Gangi A: Papillary renal cell carcinoma in allograft kidney. Eur Radiol 15: 661-5, 2005
104. Lam JS, Shvarts O, Pantuck AJ. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol. 2004; 45: 692-705.
105. Penn I. Precautions to be taken to prevent trasmission of neoplastic disease in grafting process in organ and tissue transplantation in the European Union. London: Graham and Trotan 1994; 33-41.
106. Novick AC. Nephron-sparing surgery for renal cell carcinoma.
Annu Rev Med 2002; 53: 393-407.
107. Fergany AF, Hafez KS, Novick AC. Long-term results of nephronsparing
surgery for localized renal cell carcinoma: 10-year followup J Urol 2000; 163: 442-5.
108. Gulanikar AC, Daily PP, Kilambi NK, et al. Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts
and renal cell carcinoma. Transplantation 1998; 66: 1669-72.
109. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease:
potential factors involved -editorial-. Am J Nephrol 1998; 18: 89-95.
110. Stopper H, Meysen T, Bockenforde A, et al. Increased genomic damage in lymphocytes of patients before and after long-term maintenance hemodialysis therapy. Am J Kidney Dis 1999; 34: 433-7.
111. Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003; 14:
197-207.
112. Ishikawa I. Uremic acquired renal cystic disease: Natural history and complications. Nephron 1991; 58: 257-67.
113. Horiguchi T, Ishikawa I. Immunohistochemical study in acquired cystic disease of the kidney: expression of vimentin, epidermal
growth factor, epidermal growth factor receptor and c-erb B2 gene product. Nippon Jinzo Gakkai Shi 1993; 35: 797-807.
114. Gehrig JJ Jr, Gottheiner TI, Swenson RS. Acquired cystic disease of end-stage kidney. Am J Med 1985; 79: 609-20.
115. Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore). 1990; 69: 217-26.
116. Goldfarb DA, Neumann HPH, Penn I, et al. Result of renal transplantation in patients with renal cell carcinoma and von Hippel-
Lindau disease. Transplantation 1997; 64: 1726-9.
117. Doublet JD, Peraldi MN, Gattegno B, et al. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol. 1997; 158: 42-4.
118. Hoshida Y, Nakanishi H, Shin M, et al. Renal neoplasias in patients receiving dialysis and renal transplantation: clinico-pathological
features and p53 gene mutations. Transplantation 1999; 68: 385-90.
119. Pope JC, Koch MO, Bluth RF. Renal cell carcinoma in patients with end stage renal disease: a comparison of clinical significance in
patients receiving hemodialysis and those with renal transplants.
Urology 1994; 44: 497-501.
120. Pfister C, Etienne I, Gobet F, et al. Adenocarcinoma of renal allograft as a complication at 5 years. Transplantation 1999; 68: 1608- 10.
121. Park KI, Inoue H, Kim CJ, et al. Nephron sparing surgery for de novo cell carcinoma in an allograft kidney: a case report. Int J Urol 1997; 4: 611-4.
122. THON ,KLIEM, Truss Anton Kuczyk Stief,Brunkhorst De novo urothelial carcinoma of the upper and lower urinary tract in kidnet-tranplation patients whit end-stage analgesic neprhopathy. World. Urol.1995; 13:254
123. Buzzeo BD, Heisey DM, Messing EM: Bladder cancer in renal transplant recipients. Urology 50: 525-28, 1997
124. MMMaissoneuve, Agodoa, Gellert: Cancer in patient on in dialysis for end- stage renal disease : an international collaborative study. Lancet 354:90, 1999
125. European urology 44 2003 155-158
126. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome- wide search. Science 1996; 274: 1371-1374
127. Frezza et al.: non lympohid cancer after liver transplantion.
Hepatogastoenterology 44: 1172-1181, 1997
128. Codak Thisted Gerber et al.: nejm 330:242, 19994
129. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-71, 1998
130. Marcen R, Pascual J, Tato A, Villafruela JJ, Teruel JL, Rivera ME, Tenorio M, Fernandez M, Burgos FJ, Ortuno J: Renal transplant outcome after losing the first graft. Transplant Proc 35 1679-81, 2003
131. Hariharan S, Johnson CP, Bresahan BA, Taranto SE, Mcintosh MJ, Stablein D:
Improved graft survival after renal transplantation in the United States, 1988-96. N Engl J Med 342: 605-12, 2000
132. Woodle ES, Gupta M, Buell JF, Neff GW, Gross TG, First MR, Hanaway MJ, Trofe J: Prostate cancer prior to solid organ transplantation: The Israel Penn International Transplant Tumor Registry Experience. Transplant Proc 37: 958-9, 2005
133. Penn : Evolution of tansplantion candidates with pre-existing malignances. Ann transplantion 2:14, 1997
134. Abbott KC, Reynolds JC, Trespalacios FC, Cruess D, Agodoa LY, United States Renal Data System Dialysis Morbidity and Mortality Waves II/IV: Survival by time of day of hemodialysis: Analysis of United States Renal Data System Dialysis Morbidity and Mortality Waves III/IV. Am J Kidney Dis 41: 796-806, 2003
135. Penn I. De novo malignancies in pediatric organ transplant recipients.
Pediatr Transplant 1998; 2: 56-63.
